Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Farmak PJSC's Enterprise Value is ₴2,546 Mil.
Farmak PJSC's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was ₴1,463 Mil. Therefore, Farmak PJSC's EV-to-EBIT ratio for today is 1.74.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Farmak PJSC's Enterprise Value is ₴2,546 Mil.
Farmak PJSC's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was ₴1,931 Mil. Therefore, Farmak PJSC's EV-to-EBITDA ratio for today is 1.32.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Farmak PJSC's Enterprise Value is ₴2,546 Mil.
Farmak PJSC's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was ₴7,515 Mil. Therefore, Farmak PJSC's EV-to-Revenue ratio for today is 0.34.
Farmak PJSC Enterprise Value Historical Data
The historical data trend for Farmak PJSC's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Farmak PJSC's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Farmak PJSC's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmak PJSC's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Farmak PJSC's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Farmak PJSC's Enterprise Value falls into.
Farmak PJSC Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Farmak PJSC's Enterprise Value for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmak PJSC (UKEX:FARM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Farmak PJSC's current Enterprise Value is ₴2,546 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Farmak PJSC's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was ₴1,463 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Farmak PJSC's current Enterprise Value is ₴2,546 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Farmak PJSC's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was ₴1,931 Mil.
Farmak PJSC's current Enterprise Value is ₴2,546 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Farmak PJSC's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was ₴7,515 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmak PJSC Enterprise Value Related Terms
Thank you for viewing the detailed overview of Farmak PJSC's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Farmak PJSC is a Ukraine based company engaged in the production and distribution of generic pharmaceutical drugs. Its products include Endocrinology drugs, Diagnostic drugs, Cardiac drugs, and other medications. The products are mainly sold in Ukraine and exported to many other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UKEX:FARM has been successfully added to your 